Case ReportCase Series: Novel Utilization of Rho-Kinase Inhibitor for the Treatment of Corneal EdemaDavies, Emma MD Author Information Cornea and External Diseases Department, Massachusetts Eye and Ear Infirmary, Harvard Ophthalmology, Boston, MA. Correspondence: Emma Davies, MD, Massachusetts Eye and Ear Infirmary, Massachusetts Eye and Ear Infirmary Cornea and External Diseases, 243 Charles St, Boston, MA 02114 (e-mail: [email protected]). The author has no funding or conflicts of interest to disclose. Cornea 40(1):p 116-120, January 2021. | DOI: 10.1097/ICO.0000000000002421 Buy Metrics Abstract Purpose: To describe 3 cases of corneal clearance after the use of topical rho-kinase inhibitor, netarsudil, in the setting of endothelial cell dysfunction in comparison to one case without corneal clearance after the use of netarsudil. Methods: Four patients presenting to a busy academic clinical corneal practice with visual complaints from corneal edema secondary to endothelial cell dysfunction were treated with topical netarsudil one drop daily in the affected eye. Results: Corneal clearance was observed in 1) a case of peripheral corneal edema in the setting of iridocorneal endothelial syndrome after 4 weeks on netarsudil, 2) a case of corneal edema in the setting of early penetrating keratoplasty graft failure after 2-week use of netarsudil, and 3) a case of corneal edema in the setting of chronic penetrating keratoplasty graft failure after 4-week use of netarsudil. Corneal clearance was not observed in a case of corneal edema in the setting of pseudophakic bullous keratopathy from previous complicated intraocular lens exchange surgery with placement of an anterior chamber intraocular lens after the use of netarsudil for 12 weeks. Conclusions: Addition of topical rho-kinase inhibitor in the form of netarsudil can result in corneal clearance in a variety of certain cases of endothelial cell dysfunction, not previously documented in the literature. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.